ストックスクリーナーアプリを入手
0.867
1.48%
-0.013
プレマーケット:
.86
-0.007
-0.81%
前日終値:
$0.88
開ける：
$0.89
24時間の取引高:
1.02M
Relative Volume:
0.87
時価総額：
$103.48M
収益：
-
当期純損益:
$-25.91M
株価収益率:
-3.4446
EPS:
-0.2517
ネットキャッシュフロー:
$-22.73M
1週間 パフォーマンス:
-7.27%
1か月 パフォーマンス:
-6.53%
6か月 パフォーマンス:
-11.60%
1年 パフォーマンス:
+155.08%
1日の値動き範囲:
$0.8507
$0.902
1週間の範囲:
$0.8507
$1.18
52週間の値動き範囲:
$0.3258
$1.51
Oncolytics Biotech Inc Stock (ONCY) Company Profile
名前
Oncolytics Biotech Inc
セクター
電話
(403) 670-7377
住所
SUITE 325, 4350 EXECUTIVE DRIVE, SAN DIEGO, AB
Compare ONCY vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ONCY
Oncolytics Biotech Inc
|
0.867 | 105.03M | 0 | -25.91M | -22.73M | -0.2517 |
VRTX
Vertex Pharmaceuticals Inc
|
441.74 | 108.72B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
628.73 | 64.89B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
842.27 | 50.57B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.64 | 39.06B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
155.69 | 33.16B | 742.00K | -1.37B | -1.07B | -7.0731 |
Oncolytics Biotech Inc Stock (ONCY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-08-13 | 開始されました | Lake Street | Buy |
| 2022-10-06 | 開始されました | Maxim Group | Buy |
| 2021-02-17 | 開始されました | H.C. Wainwright | Buy |
Oncolytics Biotech Inc (ONCY) 最新ニュース
ONCY: Promising GI cancer data and new patent strategies position pelareorep for major milestones - TradingView
Oncolytics schedules FDA meeting on anal cancer drug pathway - Investing.com
Oncolytics Biotech (ONCY) Valuation Check As New Pelareorep RAS Combo Data Draws Investor Attention - Yahoo Finance
Oncolytics Biotech (NASDAQ: ONCY) director Stephen Glover files initial Form 3 - Stock Titan
Oncolytics Biotech (NASDAQ: ONCY) grants director 30,000 options - Stock Titan
VersaFi ferme les marchés - Barchart.com
ONCOLYTICS BIOTECH (ONCY) CMO awarded 260,000 stock options at $1.06 - Stock Titan
Oncolytics Biotech (ONCY) COO discloses 500,000-share stock option holding - Stock Titan
ONCOLYTICS BIOTECH (ONCY) director receives 30,000 stock options at $1.06 - Stock Titan
Oncolytics Biotech (NASDAQ: ONCY) grants director Rigby 30,000 options - Stock Titan
ONCOLYTICS BIOTECH (NASDAQ: ONCY) director granted options on 30,000 shares at $1.06 - Stock Titan
ONCOLYTICS (ONCY) CFO receives 260,000 stock options at $1.06 exercise price - Stock Titan
Oncolytics Biotech (NASDAQ: ONCY) CBO receives 260,000 stock options at $1.06 exercise price - Stock Titan
Oncolytics Biotech (NASDAQ: ONCY) CEO awarded 755,000 options at $1.06 strike - Stock Titan
ONCOLYTICS BIOTECH (ONCY) director receives 30,000 stock options grant at $1.06 - Stock Titan
ONCOLYTICS (NASDAQ: ONCY) director awarded stock options on 30,000 shares - Stock Titan
ONCOLYTICS BIOTECH (NASDAQ: ONCY) CTO awarded 260,000 stock options at $1.06 strike - Stock Titan
ONCOLYTICS BIOTECH (ONCY) director receives stock options on 30,000 shares - Stock Titan
145,000 stock options granted to Oncolytics (ONCY) COO McAdory - Stock Titan
ONCOLYTICS BIOTECH (NASDAQ: ONCY) director receives 96,000 stock options at $1.06 - Stock Titan
ONCY Stock Heads For Sixth Straight Session Of Gains – Lead Therapy Shines in Early Combination Treatment Study - Stocktwits
Why Oncolytics Biotech (ONCY) Is Up 14.5% After New Pelareorep RAS-Tumor Immune Activation Data - Sahm
Oncolytics Biotech Appoints Steve Glover to Board and Promotes John McAdory to COO - geneonline.com
Oncolytics Biotech Inc - Baystreet.ca
Oncolytics appoints Glover to board, promotes McAdory to COO - Investing.com UK
Signs of Abundant Global Supplies Undercut Sugar Prices - Barchart.com
Wall Street May Still Be Looking at the Old Oncolytics Story - Barchart.com
Best Compounded Tirzepatide Online Provider (2026) Report Published by Kinross Research - Barchart.com
Oncolytics Biotech® Announces Appointment of Steve Glover to Board of Directors and Promotion of John McAdory to Chief Operating Officer - The IFP
Oncolytics appoints Glover to board, promotes McAdory to COO By Investing.com - Investing.com Canada
Oncolytics Biotech® Announces Appointment of Steve Glover - GlobeNewswire
Oncolytics (ONCY) Reports Promising Preclinical Study Results - GuruFocus
Oncolytics Biotech Reports Positive Preclinical Data for Pelareorep and RAS Inhibitor Combo in Solid Tumors - Minichart
Oncolytics Biotech (Nasdaq: ONCY) posts early pelareorep RAS-combo data - Stock Titan
Lab data show stronger RAS cancer combo; pancreatic, colorectal studies next - Stock Titan
How Is Pfizer's Stock Performance Compared to Other Healthcare Stocks? - Barchart.com
From Ambrx to Oncolytics: Why Jared Kelly Believes the Market May Be Missing the Bigger Oncology Story - ACCESS Newswire
ONCY Stock Chart | ONCOLYTICS BIOTECH INC (NASDAQ:ONCY) - ChartMill
ONCY Reiterated by HC Wainwright & Co. -- Price Target Maintained at $10 - GuruFocus
Analyst Jared Kelly Highlights Potential Opportunities for Oncolytics Biotech in Oncology Sector - geneonline.com
H.C. Wainwright reiterates Oncolytics Biotech stock rating at buy - Investing.com UK
H.C. Wainwright reiterates Oncolytics Biotech stock rating at buy By Investing.com - Investing.com Australia
Oncolytics (ONCY) to Present Key Trial Data at 2026 ASCO Annual Meeting - GuruFocus
Oncolytics Biotech Reports New Clinical Data on Pelareorep for Pancreatic and Gastrointestinal Cancers in 2026 8-K Filing - Minichart
Stocks in play: Oncolytics Biotech Inc - Barchart.com
Oncolytics Biotech (Nasdaq: ONCY) shows pelareorep immune activation data at ASCO 2026 - Stock Titan
Oncolytics Biotech® to Present Data at ASCO 2026 Reinforcing Pelareorep’s Potential Across Gastrointestinal Tumors - GlobeNewswire
New cancer immunotherapy linked to tumor volume drops at ASCO - Stock Titan
ONCY Stock Price, Quote & Chart | ONCOLYTICS BIOTECH INC (NASDAQ:ONCY) - ChartMill
Oncolytics Biotech® Announces Receipt of Nasdaq Notification Let - GuruFocus
ONCY: Aligns with FDA on pivotal trial for Pelareorep in anal cancer - MSN
Oncolytics Biotech Inc (ONCY) 財務データ
収益
当期純利益
現金流量
EPS
2.89%
0.19%
大文字化:
|
ボリューム (24 時間):